Sami Corwin
Stock Analyst at William Blair
(n/a)
# 4,471
Out of 4,829 analysts
9
Total ratings
n/a
Success rate
-57.31%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sami Corwin
Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
CRGX CARGO Therapeutics | Downgrades: Market Perform | n/a | $4.03 | - | 2 | Jan 30, 2025 | |
APLT Applied Therapeutics | Downgrades: Market Perform | n/a | $0.40 | - | 1 | Dec 23, 2024 | |
TNYA Tenaya Therapeutics | Initiates: Outperform | n/a | $0.41 | - | 1 | Jun 10, 2024 | |
NGNE Neurogene | Initiates: Outperform | n/a | $14.73 | - | 1 | Mar 21, 2024 | |
MESO Mesoblast | Downgrades: Market Perform | n/a | $10.97 | - | 1 | Aug 4, 2023 | |
CRSP CRISPR Therapeutics AG | Reinstates: Outperform | $75 | $35.62 | +110.56% | 1 | May 30, 2023 | |
LEGN Legend Biotech | Initiates: Market Perform | n/a | $31.78 | - | 1 | May 25, 2023 | |
QURE uniQure | Initiates: Outperform | $66 | $12.79 | +416.03% | 1 | Oct 27, 2021 |
CARGO Therapeutics
Jan 30, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $4.03
Upside: -
Applied Therapeutics
Dec 23, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $0.40
Upside: -
Tenaya Therapeutics
Jun 10, 2024
Initiates: Outperform
Price Target: n/a
Current: $0.41
Upside: -
Neurogene
Mar 21, 2024
Initiates: Outperform
Price Target: n/a
Current: $14.73
Upside: -
Mesoblast
Aug 4, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $10.97
Upside: -
CRISPR Therapeutics AG
May 30, 2023
Reinstates: Outperform
Price Target: $75
Current: $35.62
Upside: +110.56%
Legend Biotech
May 25, 2023
Initiates: Market Perform
Price Target: n/a
Current: $31.78
Upside: -
uniQure
Oct 27, 2021
Initiates: Outperform
Price Target: $66
Current: $12.79
Upside: +416.03%